Malaria in Early Life Study
|ClinicalTrials.gov Identifier: NCT02001428|
Recruitment Status : Unknown
Verified February 2016 by Dr. Jeanne Rini Poespoprodjo, Gadjah Mada University.
Recruitment status was: Recruiting
First Posted : December 4, 2013
Last Update Posted : February 18, 2016
The purpose of this study is to assess the effectiveness of different malaria control strategies in the first year of life.
The effectiveness of delivering an intermittent screening and treatment programme with dihydroartemisinin-piperaquine (DHP), linked to local immunization programmes, will be compared to the current practice of passive case detection of malaria.
This study has two objectives:
- To assess the effectiveness of intermittent screening and treatment with dihydroartemisinin-piperaquine (DHP) administered at 2, 3, 4 and 9 months of age compared with the current practice of passive detection and treatment for malaria in an area with high drug resistance levels to both P. falciparum and P. vivax.
- To evaluate the safety, efficacy and population pharmacokinetics of DHP in children under 1 year of age.
|Condition or disease||Intervention/treatment|
|Plasmodium Falciparum Malaria Plasmodium Vivax Malaria||Drug: dihydroartemisinin-piperaquine|
Infant malaria is a major public health issue in Timika, Papua (Indonesia) and the risk starts at birth with the majority of malaria, mostly asymptomatic, in the first 3 days of life. Malaria infection is associated with severe complications, such as severe anaemia and respiratory distress, and can be fatal.
The emergence of multidrug resistant malaria poses a significant health risk to this vulnerable group. In addition, due to non-specific symptoms of malaria found in this age group, the diagnosis is often missed. Early detection and prompt treatment with an effective antimalarial drug is the key to prevent adverse outcomes from malaria in the first year of life.
The first line treatment for uncomplicated malaria in Indonesia is Dihydroartemisinin-piperaquine (DHP), an ACT that has been shown to be highly efficacious in this region, although experience of its use in infants less than one year old is limited.
Although the World Health Organization recommends antimalarial drug efficacy trials in infants, most ACT efficacy studies include children aged one year or older. Drug population pharmacokinetic studies have enrolled younger infants aged 5-6 months old, whereas Intermittent Preventive Treatment in Infants (IPTi) studies usually start with infants as young as 3 months old.
In view of the challenges to identifying an effective malaria treatment for infants in Indonesia, the proposed study has been designed to evaluate the effectiveness of delivering early detection and prompt treatment with DHP at 2, 3, 4 and 9 months of age, linked to local immunization programmes delivered at village health posts (Posyandu), in an area with high drug resistance levels to both P. falciparum and P. vivax. The effectiveness of this approach will be compared to the current practice of passive case detection. We will also define the efficacy and pharmacokinetic profile of DHP in infancy and monitor the safety and toxicity of its use.
The proposed study will enrol 756 infants across 5 health centres in Papua, Indonesia. Infants will be recruited from pregnant mothers who are enrolled as participants of the concurrent STOPMiP trial - a clinical research study which aims to evaluate intermittent screening and treatment (IST) or intermittent preventive therapy (IPT) with DHP in pregnant women in Indonesia.
The trial result will inform policy makers in Indonesia, and internationally, on the effectiveness of different malaria control strategies in the first year of life.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||756 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Intermittent Screening and Treatment for the Control of Malaria in the First Year of Life in Papua, Indonesia: A Cluster Randomized Controlled Trial|
|Study Start Date :||May 2014|
|Estimated Primary Completion Date :||April 2016|
|Estimated Study Completion Date :||April 2017|
Experimental: Intermittent Screening and Treatment
Infants enrolled at Village health posts will be randomly allocated to receive intermittent screening and treatment (IST) on every scheduled immunization visit at 2, 3, 4 and 9 months of age. Infants in this group will be screened for malaria by Rapid Diagnostic Test (RDT), and if positive, treated with dihydroartemisinin-piperaquine (DHP). Infants will also receive follow up home visits at 6 and 12 months.
Participating infants with uncomplicated malaria will be treated with a three day course (1 dose/day) of DHP (containing 40 mg dihydroartemisinin and 320 mg piperaquine) administered as a total dose over three days of 6mg/kg of dihydroartemisinin and 57 mg/kg of piperaquine.
Other Name: DHP
No Intervention: Passive Case Detection
Infants in the control arm will only be checked for malaria if they have fever, or history of fever in the 24 hours prior to the scheduled immunization visit at 2,3,4 and 9 months of age, or at a follow up home visit at 6 and 12 months. Infants with malaria will be treated with DHP once daily for 3 days according to local treatment guidelines.
- The incidence of clinical malaria in the first year of life [ Time Frame: Total number of new clinical cases per child during the first year of life ]The total number of new clinical malaria cases from birth to one year old will be measured at one year of age.
- Proportion of infant with recurrent parasitaemia due to any species at day 42 after treatment with DHP. [ Time Frame: Parasitaemia found at day 42 after treatment with DHP ]Malaria parasitaemia is assessed by microscopy and PCR.
- Prevalence of anaemia and malaria at 6 and 12 months of age. [ Time Frame: Prevalence will be assessed at 6 and 12 months of age ]
- Population mean pharmacokinetic profile of Piperaquine [ Time Frame: the piperaquine level will be assessed at day 0,1,2,7,14,21,28,35 and 42 after treatment with DHP ]Key pharmacokinetic parameters, CL/F (clearance relative to bioavailability), Vss/F (Volume of distribution at steady state relative to bioavailability), t½,z (elimination half life) will be analysed.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02001428
|Contact: Jeanne R Poespoprodjo, MD, Msc, PhDemail@example.com|
|Timika Research Facility||Recruiting|
|Timika, Papua, Indonesia, 99971|
|Contact: Jeanne R Poespoprodjo, MD, Ph.D +62811490738 firstname.lastname@example.org|
|Contact: Hafiidhaturrahmah , MD +6285338648900 email@example.com|
|Principal Investigator: Jeanne R Poespoprodjo, MD, Msc, PhD|
|Sub-Investigator: Enny Kenangalem, MD, MSc, PhD|
|Principal Investigator:||Jeanne R Poespoprodjo, MD, MSc, PhD||University of Gadjah Madah|